Abata Therapeutics
Amina Abbadi is an accomplished researcher with extensive experience in nonclinical and translational program development. Currently serving as the Director and Research Lead at Abata Therapeutics since January 2023, Amina has previously held key positions such as Research Program Manager at Shriners Hospitals for Children and Scientific Group Lead at Harvard University, where Amina focused on gene therapy for junctional epidermolysis bullosa. Amina's tenure at Cleveland Clinic includes roles as Research Associate and K12 Scholar in Immersive Training in Glycosciences, highlighting the capability to secure significant grant funding and mentor future scientists. Amina holds a Ph.D. in Bioanalytical Clinical Chemistry from Cleveland State University-Cleveland Clinic.
This person is not in the org chart
This person is not in any offices
Abata Therapeutics
1 followers
Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.